HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

3-(4-(4-Chlorophenyl)cyclohexyl)-4-hydroxynaphthalene-1,2-dione

HCID 74989
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
137732-39-9
Standard SMILES
O=C1C(=O)c2ccccc2C(O)=C1C1CCC(c2ccc(Cl)cc2)CC1
InChIKey
BSJMWHQBCZFXBR-UHFFFAOYSA-N
Molecular formula
C22H19ClO3
Average molar mass
366.8 g/mol
Monoisotopic mass
366.1022722

Overview

Atovaquone is a naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position. It has a role as an antifungal agent, an antimalarial, an EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor, an EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor and an EC 1.10.2.2 (quinol--cytochrome-c reductase) inhibitor. It is a hydroxy-1,4-naphthoquinone and a member of monochlorobenzenes.

Names & identifiers

Preferred name
3-(4-(4-Chlorophenyl)cyclohexyl)-4-hydroxynaphthalene-1,2-dione
IUPAC
3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione
English name
cis-Atovaquone
Molecular formula
C22H19ClO3
Molecular weight
366.84

Names & synonyms

3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dioneDTXSID209166943-(4-(4-chlorophenyl)cyclohexyl)-4-hydroxynaphthalene-1,2-dioneRefChem:1066764DTXCID20888847630-425-2ATOVAQUONE95233-18-4MepronWellvonecis-AtovaquoneAcuvel
Show more names
cis-Atovaquone-d4Atovaquone EP Imp BAtovaquone Impurity 17Atovaquone EP Impurity B (RC A)Atovaquone Impurity 2(Atovaquone EP Impurity B)Atovaquone EP Impurity B (Atovaquone Related Compound A)Atovaquone EP Impurity B (Atovaquone USP Related Compound A)
137732-39-9Atavaquone94015-53-9566C80Mepron (antipneumocystic)CIS-ATOVAQUONE (RACEMIC)Atovaquone EP Impurity BBW 566C

Database identifiers

CAS
137732-39-9、94015-53-9、95233-18-4

Properties

Computed structural propertiesFilling in

XLogP
5.2
Topological polar surface area
54.4 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
3
Rotatable bonds
2
Heavy atoms
26
Formal charge
0
Complexity
595

Experimental & physicochemical properties

Drugs · 3 items

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals

LogP5.07
SolubilityPractically insoluble
Collision Cross Section174.53 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Melting point
40 °C · >40°C (dec.)
Boiling point
535 · 535.0±50.0 °C(Predicted)
Density
1.349 · 1.349±0.06 g/cm3(Predicted)
storage temp.
Room Temperature, under inert atmosphere
solubility
Chloroform (Slightly), Dichloromethane (Slightly, Acetonitrile)
pka
5.01 · 5.01±0.10(Predicted)
form

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Hazard information

Hazard Classes and CategoriesSkin Irrit. 2 (100%)

Safety data

wgk
3
Storage Class
11 - Combustible Solids

Chemistry & industry

Pharmacology

ATC CodeP01AX06
Protein BindingAtovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 µg/mL.
Pharmacodynamics · 1 item

Atovaquone is a highly lipophilic drug that closely resembles the structure [ubiquinone]. Its inhibitory effect being comparable to ubiquinone, atovaquone can act by selectively affecting mitochondrial electron transport and parallel processes such as ATP and pyrimidine biosynthesis in atovaquone-responsive parasites. Cytochrome bc1 complex (complex III) seems to serve as a highly discriminating molecular target for atovaquone in Plasmodia. There is no significant risk for myelosuppression associated with atovaquone, making this drug a beneficial therapeutic agent for recipients of bone marrow transplantation.

Mechanism of Action · 1 item

The mechanism of action against <i>Pneumocystis carinii</i> has not been fully elucidated. In Plasmodium species, the site of action appears to be the cytochrome bc1 complex (Complex III). Several metabolic enzymes are linked to the mitochondrial electron transport chain via ubiquinone. Inhibition of electron transport by atovaquone will result in indirect inhibition of these enzymes. The ultimate metabolic effects of such blockade may include inhibition of nucleic acid and ATP synthesis. Atovaquone also has been shown to have good <i>in vitro</i> activity against <i>Toxoplasma gondii</i>.

Biological Half-Life2.2 to 3.2 days
Metabolism/MetabolitesSome evidence suggests limited metabolism (although no metabolites have been identified).
Absorption, Distribution and Excretion · 4 items

The bioavailability of atovaquone is low and variable and is highly dependent on formulation and diet. Bioavailability of the suspension increases two-fold when administered with meals. When administered with food, bioavailability is approximately 47%. Without food, the bioavailability is 23%.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
PubChem CID
74989
DTXSID
DTXSID20916694
ChEMBL
CHEMBL471792、CHEMBL519462
ChEBI
CHEBI:575568
UNII
F1W7QUV0KI、Y883P1Z2LT
EC Number
689-795-9
Nikkaji
J1.549.967B、J389.528I
Solid
color
Pale Yellow to Light Yellow
Major Application
pharmaceutical (small molecule)
FDA UNII
1 W7QUV0KI · F1W7QUV0KI
UNSPSC Code
41116107 · 41116107
NACRES
24 · NA.24
WGK Germany
3 · 3
Storage Class
11 · 11 - Combustible Solids

The half-life of atovaquone is long due to presumed enterohepatic cycling and eventual fecal elimination. There was little or no excretion of atovaquone in the urine (less than 0.6%).

0.60 ± 0.17 L/kg

10.4 +/- 5.5 ml/min [HIV-infected patients receiving IV administration]

Applications

Usescis-Atovaquone is the cis-isomer of Atovaquone (A793500), a hydroxynaphthoquinone derivative that inhibits mitochondrial electron transport.

Additional notes · 1 item

DefinitionChEBI: Atovaquone is a naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position. It has a role as an antimalarial, an antifungal agent, an EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor, an EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor and an EC 1.10.2.2 (quinol--cytochrome-c reductase) inhibitor. It is a member of monochlorobenzenes and a hydroxy-1,4-naphthoquinone.